• An uncommon but serious bacterial infection caused by Neisseria meningitidis1,2
  • Symptoms can progress to death in as few as 24 hours1,3
  • Of those who contract meningococcal disease, between 10% and 15% die from complications despite appropriate antibiotic treatment2
  • About 11% to 19% of survivors suffer permanent sequelae, such as seizures/neurological problems, loss of limbs, kidney damage, hearing loss, skin scarring, and brain damage1,4,5

According to CDC, serogroup B caused the majority of all US meningococcal cases in patients 16-23 years of age from 2017 to 20216

Cases of Meningococcal Disease in the US by MenB Serogroup and MenACWY Serogroups and Other* Serogroups

Pie Chart displaying B = 53%; A, C, W, Y other* = 47%


*Other, nongroupable, unknown

As of 2022, CDC survey data showed the MenB vaccination rate among adolescents was low7

Only 29.4%

of 17-year-olds had received at least 1 dose of a MenB vaccine

ONLY 11.9% of 17-year-olds had received 2 doses or more of a MenB vaccine.7

Follow the CDC recommendation

CDC recommends a primary series for adolescents not at increased risk, aged 16-23 years (preferred age 16-18 years), based on shared clinical decision-making.8-10

One dose is not enough!

Your patients need more than 1 dose to complete a MenB vaccination series.9 Make sure your patients are fully vaccinated against MenB.

Vaccination may not protect all recipients.

Dose Icon

See the impact of MenB

CDC=Centers for Disease Control and Prevention; MenACWY=meningococcal serogroups A, C, W, and Y; MenB=meningococcal serogroup B.